The MONITOR Study: Remote Monitoring Of a Nutrition Intervention To Optimize Treatment Response
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
- Behavioral: Quality fo Life Questionnaire (FHSI)
- Behavioral: Vioscreen Food Frequency Questionnaire (FFQ)
- Behavioral: NutritionCoaching
- Behavioral: Follow-Up Survey
- Behavioral: Functional Assessment of Anorexia/Cachexia Treatment (FAACT) Questionnaire
- Behavioral: Patient Reported Outcomes Measure- Cognitive Function (PROMIS-Cog) Questionnaire
- Behavioral: Educational Handouts
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33612
- Moffitt Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men or women 18 years of age or more
- Newly diagnosed, in place tumors of the pancreas
- No documented or observable psychiatric or neurological disorders that would interfere with study participation (e.g., dementia, psychosis)
- Able to speak and read English
- Able to consume food orally
- Chemotherapy naive
- Scheduled to receive treatment with chemotherapy
- Able to provide verbal informed consent
Exclusion Criteria:
- Women who are pregnant
- Pancreatic cancer not the primary diagnosis
- Patients on enteral or parental nutrition
- Patients with metastatic pancreatic cancer
- Patients with evidence of impeding bowel obstruction
- Patients presenting with ascites
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: MONITOR group: Monitoring of a Nutrition Intervention to Optimize treatment Response
Participants randomized to the MONITOR arm will be provided dietary coaching biweekly to discuss nutrition concerns, anti-inflammatory diet compliance, and set SMART goals based on their most recent Vioscreen food frequency questionnaires.
|
Participants will take a survey at baseline and visit 2 (weeks 6-8), and visit 3 (week 10-14).
The Functional Assessment of Cancer Therapy Hepatobiliary Cancer Symptom Index-8 (FHSI) questionnaire uses a 5-point Likert-type scale, 0=not at all and 4=Very much.
A lower total score indicates better quality of life.
Participants will receive a web-based link and information to complete VioScreen, a web-based food frequency questionnaire, which allows participants to choose the average frequency of consumption of food items over a given time frame (1 month, 3 month, 1 year, etc.) on a Likert scale with choices ranging by individual questions.
Total energy and nutrient intake is estimated by summing intakes from each food based on the selected portion size, reported frequency of consumption, and nutrient content of each food item.
Anti-inflammatory and pro-inflammatory dietary patterns are calculated using the energy-adjusted dietary inflammatory index (DII) score to represent the inflammatory potential of an individual's overall diet, using data from FFQ responses.
Higher DII scores represent more pro-inflammatory diets while lower (i.e., more negative) DII scores represent more anti-inflammatory diet.
Participants will receive bi-weekly nutrition coaching on anti-inflammatory dietary patterns and foods.
Participants will complete a custom exit/follow up survey regarding relevance, acceptability, intervention length and timing, an barriers/facilitators.
This survey contains 38 questions scored from 1 -Strongly agree to 5-Strongly disagree.
A lower score indicates patient satisfaction with the program and the skills and knowledge gained in the program.
The FAACT questionnaire uses a 5 point Likert-type scale, 0=Not at all, 4=Very much.
A higher score indicates better appetite and quality of life.
Participants will complete the PROMIS-Cog form which measures self-reported cognitive deficits.
The questionnaire uses a 5 point Likert-type scale, 1=Very often and 5=Never.
A higher score indicates higher cognitive function.
|
|
Active Comparator: Standard Usual Care
Standard Usual Care participants will receive usual nutrition care received in the Moffitt Cancer Center pancreatic clinic, in addition to handouts on diet.
|
Participants will take a survey at baseline and visit 2 (weeks 6-8), and visit 3 (week 10-14).
The Functional Assessment of Cancer Therapy Hepatobiliary Cancer Symptom Index-8 (FHSI) questionnaire uses a 5-point Likert-type scale, 0=not at all and 4=Very much.
A lower total score indicates better quality of life.
Participants will complete a custom exit/follow up survey regarding relevance, acceptability, intervention length and timing, an barriers/facilitators.
This survey contains 38 questions scored from 1 -Strongly agree to 5-Strongly disagree.
A lower score indicates patient satisfaction with the program and the skills and knowledge gained in the program.
The FAACT questionnaire uses a 5 point Likert-type scale, 0=Not at all, 4=Very much.
A higher score indicates better appetite and quality of life.
Participants will complete the PROMIS-Cog form which measures self-reported cognitive deficits.
The questionnaire uses a 5 point Likert-type scale, 1=Very often and 5=Never.
A higher score indicates higher cognitive function.
Participants will receive educational handouts on diet.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recruitment Rate -Feasibility
Time Frame: Up to 8 months
|
The study will be deemed feasible if >/= 60% of eligible participants are enrolled
|
Up to 8 months
|
|
Retention Rate - Feasibility
Time Frame: at 12 weeks
|
The study will be deemed feasible if >/=70% of participants complete the post-intervention questionnaire
|
at 12 weeks
|
|
Adherence - Feasibility
Time Frame: at 12 weeks
|
The study will be deemed feasible if average attendance is >/=4 weeks of sessions (out of 6) for MONITOR arm
|
at 12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Participant Satisfaction with Overall Program- Acceptability
Time Frame: at 12 weeks
|
The study will be deemed acceptable based on the satisfaction score on follow-up survey.
The follow-up survey uses open-ended and likert-style questions regarding 1) relevance and applicability of the MONITOR intervention content and objective/subjective data collection methods; 2) intervention length and timing; and 3) barriers/facilitators to participation and retention.
On a 5-point Lkert-type scale, a(1) =strongly agree and e(5)=strongly disagree.
Participant Satisfaction with Overall Program is determined by a score >/=3 on a 5-point scale.
|
at 12 weeks
|
|
Participant intent to continue using skills- Acceptability
Time Frame: at 12 weeks
|
The study will be deemed acceptable based on the satisfaction score on follow-up survey.
The follow-up survey uses open-ended and likert-style questions regarding 1) relevance and applicability of the MONITOR intervention content and objective/subjective data collection methods; 2) intervention length and timing; and 3) barriers/facilitators to participation and retention.
On a 5-point Lkert-type scale, a(1) =strongly agree and e(5)=strongly disagree.
Participant intent to continue using skills- is determined by a score >/=3 on a 5-point scale.
|
at 12 weeks
|
|
Participant perception of utility of knowledge gained - Acceptability
Time Frame: at 12 weeks
|
The study will be deemed acceptable based on the satisfaction score on follow-up survey.
The follow-up survey uses open-ended and likert-style questions regarding 1) relevance and applicability of the MONITOR intervention content and objective/subjective data collection methods; 2) intervention length and timing; and 3) barriers/facilitators to participation and retention.
On a 5-point Lkert-type scale, a(1) =strongly agree and e(5)=strongly disagree.
Participant perception of utility of knowledge gained is determined by a score >/=3 on a 5-point scale.
|
at 12 weeks
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Treatment Effect - Quality of Life
Time Frame: at Baseline, and at 6 and 12 weeks
|
Quality of Life will be measured using the FACT-Hep questionnaire.
Participants will take the Functional Assessment of Cancer Therapy Hepatobiliary Cancer Symptom 8 Item Version (FHSI) questionnaire which uses a 5-point likert-type scale, 0=not at all and 4=Very much.
A lower total score indicates better quality of life.
|
at Baseline, and at 6 and 12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Pamela Hodul, MD, Moffitt Cancer Center
- Principal Investigator: Sylvia Crowder, PhD, Moffitt Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Neoplasms by Site
- Neoplasms
- Digestive System Neoplasms
- Digestive System Diseases
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Health Care Quality, Access, and Evaluation
- Investigative Techniques
- Epidemiologic Methods
- Data Collection
- Health Care Evaluation Mechanisms
- Quality of Health Care
- Public Health
- Environment and Public Health
- Surveys and Questionnaires
Other Study ID Numbers
Other Study ID Numbers
- MCC-22523
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.